Endometriosis: Alternative methods of medical treatment

International Journal of Women's Health

Volumn 7, Issue , 2015, Pages 595-603

  Muñoz Hernando, Leticia ^a   Muñoz Gonzalez, Jose L ^a   Marqueta Marques, Laura ^a   Alvarez Conejo, Carmen ^a   Tejerizo García, Álvaro ^a   Lopez Gonzalez, Gregorio ^a   Villegas Muñoz, Emilia ^b   Martin Jimenez, Angel ^c   Jiménez López, Jesús S ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL SON LLÀTZER   (Spain)

Author keywords

Anti TNF ; Antiangiogenic factors; Aromatase inhibitors; Endometrial tissue; GnRH antagonists; Hormonal treatments; Pharmacological treatment options; Selective progesterone receptor modulators

Indexed keywords

ANASTROZOLE; ANGIOGENESIS INHIBITOR; AROMATASE INHIBITOR; ASOPRISNIL; ATORVASTATIN; BEVACIZUMAB; CELECOXIB; CETRORELIX; CYCLOOXYGENASE 2 INHIBITOR; DANAZOL; ELAGOLIX; FUMAGILLIN; GANIRELIX; GONADORELIN ANTAGONIST; GOSERELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LETROZOLE; MIFEPRISTONE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PENTOXIFYLLINE; PLACEBO; PROGESTERONE RECEPTOR MODULATOR; TRIPTORELIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASCULOTROPIN ANTIBODY;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ACUTE LEUKEMIA; ANXIETY; ARTICLE; BLEEDING; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIOSIS; GONADOTROPIN RELEASE; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; INFUSION RELATED REACTION; META ANALYSIS (TOPIC); METRORRHAGIA; MOOD DISORDER; MYALGIA; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEINURIA; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); THROMBOSIS; TONSILLITIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84936866067     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S78829     Document Type: Article

References (74)

1. Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010; 362(25):2389–2398.
2. Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Hum Reprod. 2013;28(6):1552–1568.
3. Streuli I, de Ziegler D, Santulli P. An update on the pharmacological management of endometriosis. Expert Opin Pharmacother. 2013;14(3): 291–305.
4. Allen C, Hopewell S, Prentice A, Gregory D. Nonsteroidal anti-infammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. 2009;2:CD004753.
5. Dunselman GA, Vermeulen N, Becker C, et al; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–412.
6. Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril. 1993;60:75–79.
7. Davis LJ, Kennedy SS, Moore J, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev. 2007; 3:CD001019.
8. Vercellini P, Barbara G, Somigliana E, Bianchi S, Abbiati A, Fedele L. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril. 2010;93:2150–2161.
9. Abou-Setta AM, Houston B, Al-Inany HG, Farquhar C. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Database Syst Rev. 2013;1:CD005072.
10. Farquhar C, Prentice A, Singla AA, Selak V. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev. 2007;4: CD000068.
11. Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev. 2012; 3:CD002122.
12. Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010;12:CD008475.
13. Huirne JA, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet. 2001;358(9295):1793–1803.
14. Diamond MP, Carr B, Dmowski WP, et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci. 2014;21:363–371.
15. Simpson ER, Mahendroo MS, Means GD, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev. 1994;15:342–355.
16. Bulun SE, Sharda G, Rink J, Sharma S, Simpson ER. Distribution of aromatase P450 transcripts and adipose fbroblasts in the human breast. J Clin Endocrinol Metab. 1996;81:1273–1277.
17. Colette S, Lousse JC, Defrère S, et al. Absence of aromatase protein and mRNA expression in endometriosis. Hum Reprod. 2009;24: 2133–2141.
18. Soysal S, Soysal ME, Ozer S, Gul N, Gezgin T. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 2004;19:160–167.
19. Alborzi S, Hamedi B, Omidvar A, Dehbashi S, Alborzi S, Alborzi M. A comparison of the effect of short-term aromatase inhibitor (letro-zole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. Arch Gynecol Obstet. 2011;284:105–110.
20. Roghaei MA, Tehrany HG, Taherian A, Koleini N. Effects of letrozole compared with danazol on patients with confrmed endometriosis: a randomized clinical trial. Int J Fertili Steril. 2010;4:67–72.
21. Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethin-drone acetate: a pilot study. Fertil Steril. 2004;81:290–296.
22. Remorgida V, Abbamonte HL, Ragni N, Fulcheri E, Ferrero S. Letrozole and norethisterone acetate in rectovaginal endometriosis. Fertil Steril. 2007; 88:724–726.
23. Ferrero S, Camerini G, Seracchioli R, Ragni N, Venturini PL, Remorgida V. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod. 2009;24:3033–3041.
24. Ferrero S, Camerini G, Ragni N, et al. Letrozole and norethisterone acetate in colorectal endometriosis. Eur J Obstet Gynecol Reprod Biol. 2010;150:199–202.
25. Amsterdam LL, Gentry W, Jobanputra S, Wolf M, Rubin SD, Bulun SE. Anastrazole and oral contraceptives: a novel treatment for endometrio-sis. Fertil Steril. 2005;84:300–304.
26. Remorgida V, Abbamonte LH, Ragni N, Fulcheri E, Ferrero S. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis. Aust N Z J Obstet Gynaecol. 2007;47:222–225.
27. Hefer LA, Grimm C, van Trotsenburg M, Nagele F. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovagi-nal endometriosis: a pilot study. Fertil Steril. 2005;84:1033–1036.
28. Colette S, Donnez J. Are aromatase inhibitors effective in endometriosis treatment? Expert Opin Investig Drugs. 2011;20(7):917–931.
29. Chwalisz K, Garg R, Brenner RM, Schubert G, Elger W. Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis. Ann N Y Acad Sci. 2002;955:373–388.
30. Schaff EA. Mifepristone: ten years later. Contraception. 2010;81: 1–7.
31. Im A, Appleman LJ. Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology. Expert Opin Pharmacother. 2010;11:481–488.
32. Donnez J, Tatarchuk TF, Bouchard P, et al; PEARL I Study Group. Ulipristal acetate versus placebo for fbroid treatment before surgery. N Engl J Med. 2012;366:409–420.
33. Donnez J, Tomaszewski J, Vázquez F, et al; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fbroids. N Engl J Med. 2012;366:421–432.
34. Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Ye n SS. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril. 1996;65:23–28.
35. Kettel LM, Murphy AA, Morales AJ, Ye n SS. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol. 1998;178:1151–1156.
36. Chwalisz K, Mattia-Goldberg C, Elger W, Edmonds A. Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil. Fertil Steril. 2004;82:S83–S84.
37. Bulun SE. Mechanism of disease. Endometriosis. N Engl J Med. 2009; 360:268–279.
38. Tseng JF, Ryan IP, Milam TD, et al. Interleukin-6 secretion in vitro is up-regulated in ectopic and eutopic endometrial stromal cells from women with endometriosis. J Clin Endocrinol Metab. 1996;81:1118–1122.
39. Hornung D, Ryan IP, Chao VA, Vigne JL, Schriock ED, Taylor RN. Immunolocalization and regulation of the chemokine RANTES in human endometrial and endometriosis tissues and cells. J Clin Endocrinol Metab. 1997;82:1621–1628.
40. Koninckx PR, Craessaerts M, Timmerman D, Cornillie F, Kennedy S. Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod. 2008;23(9): 2017–2023.
41. Lu D, Song H, Shi G. Anti-TNF-α treatment for pelvic pain associated with endometriosis. Cochrane Database Syst Rev. 2013;3: CD008088.
42. Sampson JA. Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927;14:422–469.
43. Groothuis PG, Nap AW, Winterhager E, Grümmer R. Vascular development in endometriosis. Angiogenesis. 2005;8:147–156.
44. Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update. 2007;13:331–342.
45. Hur SE, Lee JY, Moon HS, Chung H W. Angiopoietin-1, angiopoietin-2 and Tie-2 expression in eutopic endometrium in advanced endometrio-sis. Mol Hum Reprod. 2006;12:421–426.
46. Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update. 2012;18:682–702.
47. Hull ML, Charnock-Jones DS, Chan CL, et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab. 2003; 88:2889–2899.
48. Nap AW, Griffoen AW, Dunselman GA, et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab. 2004;89:1089–1095.
49. Nap AW, Dunselman GA, Griffioen AW, Mayo KH, Evers JL, Groothuis PG. Angiostatic agents prevent the development of endo-metriosis-like lesions in the chicken chorioallantoic membrane. Fertil Steril. 2005;83:793–795.
50. Ricci AG, Olivares CN, Bilotas MA, Meresman GF, Barañao RI. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis. Reprod Sci. 2011;18: 614–622.
51. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788–1795.
52. Dahut WL, Lakhani NJ, Gulley JL, et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther. 2006;5:22–27.
53. Kulke MH, Chan JA, Meyerhardt JA, et al. A prospective phase II study of 2-methoxyestradiol administered in combination with bevaci-zumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol. 2011;68:293–300.
54. Becker CM, Sampson DA, Rupnick MA, et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril. 2005;84(suppl 2):1144–1155.
55. Dabrosin C, Gyorffy S, Margetts P, Ross C, Gauldie J. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am J Pathol. 2002;161:909–918.
56. Satchi-Fainaro R, Puder M, Davies JW, et al. Targeting angiogen-esis with a conjugate of HPMA copolymer and TNP-470. Nat Med. 2004;10:255–261.
57. Dulak J, Jozkowicz A. Anti-angiogenic and anti-infammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005;5:579–594.
58. Oktem M, Esinler I, Eroglu D, Haberal N, Bayraktar N, Zeyneloglu HB. High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod. 2007;22:1474–1480.
59. Bruner-Tran KL, Osteen KG, Duleba AJ. Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metab. 2009;94:2489–2494.
60. Ota H, Igarashi S, Sasaki M, Tanaka T. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod. 2001;16:561–566.
61. Cho S, Park SH, Choi YS, et al. Expression of cyclooxygenase-2 in eutopic endometrium and ovarian endometriotic tissue in women with severe endometriosis. Gynecol Obstet Invest. 2010;69:93–100.
62. Olivares C, Ricci A, Bilotas M, Barañao RI, Meresman G. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertil Steril. 2011;96:428–433.
63. Machado DE, Berardo PT, Landgraf RG, et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model. Fertil Steril. 2010;93: 2674–2679.
64. Cobellis L, Razzi S, De Simone S, et al. The treatment with a COX-2 specifc inhibitor is effective in the management of pain related to endo-metriosis. Eur J Obstet Gynecol Reprod Biol. 2004;116:100–102.
65. Burnier M. The safety of rofecoxib. Expert Opin Drug Saf. 2005;4(3): 491–499.
66. Olivares CN, Bilotas MA, Ricci AG, Barañao RI, Meresman GF. Anastrozole and celecoxib for endometriosis treatment, good to keep them apart? Reproduction. 2013;145(2):119–126.
67. Dmowski WP, Braun DP. Immunology of endometriosis. Best Pract Res Clin Obstet Gynaecol. 2004;18:245–263.
68. Vlahos NF, Gregoriou O, Deliveliotou A, et al. Effect of pentoxifyl-line on vascular endothelial growth factor C and fk-1 expression on endometrial implants in the rat endometriosis model. Fertil Steril. 2010;93:1316–1323.
69. Olive DL, Lindheim SR, Pritts EA. New medical treatments for endo-metriosis. Best Pract Res Clin Obstet Gynaecol. 2004;18:319–328.
70. Kamencic H, Thiel JA. Pentoxifylline after conservative surgery for endometriosis: a randomized, controlled trial. J Minim Invasive Gynecol. 2008;15:62–66.
71. Alborzi S, Ghotbi S, Parsanezhad ME, Dehbashi S, Alborzi S, Alborzi M. Pentoxifylline therapy after laparoscopic surgery for different stages of endometriosis: a prospective, double-blind, randomized, placebo-controlled study. J Minim Invasive Gynecol. 2007;14(1):54–58.
72. Balasch J, Creus M, Fabregues F, et al. Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endo-metriosis: a pilot randomized clinical trial. Hum Reprod. 1997;12(9): 2046–2050.
73. Creus M, Fabregues F, Carmona F, Del Pino M, Manau D, Balasch J. Combined laparoscopic surgery and pentoxifylline therapy for treatment of endometriosis-associated infertility: a preliminary trial. Hum Reprod. 2008;23(8):1910–1916.
74. Lu D, Song H, Li Y, Clarke J, Shi G. Pentoxifylline for endometriosis. Cochrane Database Syst Rev. 2012;1:CD007677.